Dyne Therapeutics (NASDAQ:DYN) Trading Down 5% – Should You Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN)’s share price traded down 5% during mid-day trading on Friday . The stock traded as low as $16.07 and last traded at $15.91. 128,764 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 2,676,205 shares. The stock had previously closed at $16.76.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on DYN shares. Baird R W raised shares of Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Royal Bank of Canada reiterated an “outperform” rating and set a $45.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. HC Wainwright reiterated a “buy” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a research note on Friday, January 10th. Guggenheim reiterated a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. Finally, Robert W. Baird initiated coverage on shares of Dyne Therapeutics in a research note on Friday, December 13th. They set an “outperform” rating and a $46.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $49.91.

Dyne Therapeutics Trading Down 7.5 %

The stock has a market cap of $1.58 billion, a P/E ratio of -4.35 and a beta of 1.11. The company’s fifty day simple moving average is $21.24 and its 200-day simple moving average is $30.95.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Activity

In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,455 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $40,914.60. Following the completion of the transaction, the senior vice president now owns 127,078 shares of the company’s stock, valued at $3,573,433.36. This represents a 1.13 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Carlo Incerti sold 16,500 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $28.73, for a total value of $474,045.00. The disclosure for this sale can be found here. Insiders sold a total of 21,071 shares of company stock valued at $606,476 in the last ninety days. 20.77% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Quantbot Technologies LP bought a new stake in Dyne Therapeutics in the third quarter worth approximately $34,000. Point72 DIFC Ltd purchased a new position in shares of Dyne Therapeutics during the 3rd quarter valued at $36,000. US Bancorp DE raised its stake in shares of Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after purchasing an additional 1,212 shares during the period. Values First Advisors Inc. bought a new stake in shares of Dyne Therapeutics during the 3rd quarter valued at $62,000. Finally, KBC Group NV grew its holdings in shares of Dyne Therapeutics by 53.4% during the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after purchasing an additional 751 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.